Institutional Fund
Commodore Capital LP
New York, NYCIK 18319425 filings on record
Portfolio Value
$1.73B
Q1 2026
Holdings
36
Reported positions
New Buys
13
Opened this quarter
QoQ Change
+15.1%
from $1.50B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Relay Therapeutics Inc9.8%
- Alkermes PLC8.6%
- Enliven Therapeutics Inc7.4%
- Cogent Biosciences Inc6.4%
- Spyre Therapeutics Inc5.6%
- Tyra Biosciences Inc5.5%
- Other56.7%
Portfolio Holdings
36 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Relay Therapeutics Inc | 17.00M | $169.15M | 9.8% | 0 | Held |
| 2 | Alkermes PLC | 4.20M | $148.51M | 8.6% | +650.0K | Added |
| 3 | Enliven Therapeutics Inc | 3.27M | $128.38M | 7.4% | −1.42M | Reduced |
| 4 | Cogent Biosciences Inc | 2.89M | $111.16M | 6.4% | +691.2K | Added |
| 5 | Spyre Therapeutics Inc | 1.91M | $96.46M | 5.6% | −475.9K | Reduced |
| 6 | Tyra Biosciences Inc | 2.48M | $94.79M | 5.5% | −900.0K | Reduced |
| 7 | Celldex Therapeutics Inc New | 2.70M | $85.54M | 4.9% | +131.6K | Added |
| 8 | Nuvalent Inc | 833.6K | $85.40M | 4.9% | +283.6K | Added |
| 9 | Amylyx Pharmaceuticals Inc | 5.65M | $78.53M | 4.5% | 0 | Held |
| 10 | Kymera Therapeutics Inc | 750.0K | $62.47M | 3.6% | 0 | Held |
26 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio